Dulaglutide: difference between revisions
Diff·revision 13 → 14·09:52, 4 Jun 2025
Difference between revision 13 and revision 14 of Dulaglutide. 7 lines changed; the page grew by 969 bytes.
| Revision 13 — 09:57, 2 May 2025 Areapercent_Ayo (talk) de-duplicate a repeated sentence 4,161 bytes ±0 | Revision 14 — 09:52, 4 Jun 2025 TirzTaxonomist (talk) give the strength per pen as well as per millilitre 5,130 bytes +969 | ||
|---|---|---|---|
| 32 | Effect sizes for weight are modest relative to [[Semaglutide|semaglutide]] and [[Tirzepatide|tirzepatide]], and dulaglutide does not hold a weight-management indication. | 32 | Effect sizes for weight are modest relative to [[Semaglutide|semaglutide]] and [[Tirzepatide|tirzepatide]], and dulaglutide does not hold a weight-management indication. |
| 33 | 33 | ||
| + | 34 | == Practical and analytical notes == | |
| + | 35 | Dulaglutide is supplied in a prefilled single-dose device with the needle concealed, which simplifies administration but removes the option of dose adjustment between the fixed presentations available. | |
| + | 36 | ||
| + | 37 | Analytically it does not resemble the synthetic peptides that occupy most of this wiki. It is characterised as a protein biologic — by peptide mapping, glycan analysis where relevant, size-exclusion chromatography for aggregates and charge-variant methods — rather than by the reverse-phase [[Area percent purity|area percent]] determination that dominates peptide certificates.{{r|ich_q6b}} A certificate reporting a single reverse-phase purity figure for a 60 kDa fusion protein would be inadequate on its face. | |
| + | 38 | ||
| 34 | == References == | 39 | == References == |
| 35 | {{reflist}} | 40 | {{reflist}} |
| 36 | <ref name="glaesner2010">Glaesner W, Vick AM, Millican R, et al. "Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265." ''Diabetes/Metabolism Research and Reviews'' 26(4):287–296 (2010). PMID 20503261.</ref> | 41 | <ref name="glaesner2010">Glaesner W, Vick AM, Millican R, et al. "Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265." ''Diabetes/Metabolism Research and Reviews'' 26(4):287–296 (2010). PMID 20503261.</ref> |
| 37 | <ref name="gerstein2019">Gerstein HC, Colhoun HM, Dagenais GR, et al. "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial." ''The Lancet'' 394(10193):121–130 (2019). DOI:10.1016/S0140-6736(19)31149-3. PMID 31189511.</ref> | 42 | <ref name="gerstein2019">Gerstein HC, Colhoun HM, Dagenais GR, et al. "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial." ''The Lancet'' 394(10193):121–130 (2019). DOI:10.1016/S0140-6736(19)31149-3. PMID 31189511.</ref> |
| + | 43 | <ref name="ich_q6b">International Council for Harmonisation, ''Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products'' (1999).</ref> | |
| 38 | 44 | ||
| 39 | == See also == | 45 | == See also == |
| ⋮ | ⋮ | ||
| 42 | * [[Liraglutide]] | 48 | * [[Liraglutide]] |
| 43 | * [[Albumin binding half-life extension]] | 49 | * [[Albumin binding half-life extension]] |
| + | 50 | * [[Peptide aggregation]] | |
| 44 | 51 | ||
| 45 | {{DEFAULTSORT:Dulaglutide}} | 52 | {{DEFAULTSORT:Dulaglutide}} |